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Abstract
Background: Middle East respiratory syndrome coronavirus infection is associated with high mortality rates but
limited clinical data have been reported. We describe the clinical features and outcomes of patients admitted to an
intensive care unit (ICU) with Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
Methods: Retrospective analysis of data from all adult (>18 years old) patients admitted to our 20-bed mixed ICU
with Middle East respiratory syndrome coronavirus infection between October 1, 2012 and May 31, 2014. Diagnosis
was confirmed in all patients using real-time reverse transcription polymerase chain reaction on respiratory samples.
Results: During the observation period, 31 patients were admitted with MERS-CoV infection (mean age 59 ±
20 years, 22 [71 %] males). Cough and tachypnea were reported in all patients; 22 (77.4 %) patients had bilateral
pulmonary infiltrates. Invasive mechanical ventilation was applied in 27 (87.1 %) and vasopressor therapy in 25
(80.6 %) patients during the intensive care unit stay. Twenty-three (74.2 %) patients died in the ICU. Nonsurvivors
were older, had greater APACHE II and SOFA scores on admission, and were more likely to have received invasive
mechanical ventilation and vasopressor therapy. After adjustment for the severity of illness and the degree of organ
dysfunction, the need for vasopressors was an independent risk factor for death in the ICU (odds ratio = 18.33, 95 %
confidence interval: 1.11–302.1, P = 0.04).
Conclusions: MERS-CoV infection requiring admission to the ICU is associated with high morbidity and mortality.
The need for vasopressor therapy is the main risk factor for death in these patients.
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Background
Middle East respiratory syndrome coronavirus (MERS-
CoV) is a novel betacoronavirus that was first reported
in September 2012 [1]. By January 6, 2016, a total of
1626 laboratory-confirmed cases of infection with
MERS-CoV, including at least 586 related deaths, had
been reported to the World Health Organization [2].
Although MERS-CoV infections have been reported
from 26 countries around the world, the majority of
cases have originated in Saudi Arabia, South Korea,
the United Arab Emirates, Jordan and Qatar [3]. Inter-
human MERS-CoV transmission occurs in community
and healthcare settings [4–8]. The exact source
and mode of transmission of MERS-CoV to humans
remains uncertain. However, MERS-CoV circulates
among dromedary camels in Africa and the Middle
East with occasions of documented camel-human
inter-transmission [9].
There have been several reports outlining the clinical
features and outcomes of patients with MERS-CoV infec-
tion [7, 10–15]. However, very few have focused on critic-
ally ill patients in intensive care units (ICU) [16–18].
There is therefore a need for more data to understand the
various clinical and prognostic aspects of this potentially
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lethal disease, particularly for the most severe cases that
require admission to the ICU.
We performed a retrospective study to describe
the clinical features and outcomes of patients admitted
to our ICU with laboratory-confirmed MERS-CoV
infection.
Methods
Ethics, consent and permissions
The study was approved by the institutional review
board of Prince Sultan Military Medical City (11159
Riyadh, Saudi Arabia), a large tertiary-care referral center
in Riyadh, Saudi Arabia. Informed consent was waived
due to the retrospective, anonymous nature of data collec-
tion. We included all patients aged 18 years or more with
confirmed MERS-CoV infection who were admitted to
our 20-bed mixed medico-surgical ICU between October
1, 2012 and May 31, 2014.
Data collection
All ICU patients with a confirmed diagnosis of MERS-
CoV were registered in a special logbook. For the pur-
pose of the current study, all patients’ records were
reviewed by a senior intensivist (S. Hussain, A. Alwan,
A. Abudayah, S. Altayyar, M. Mustafa, T. Aldaghestani,
A. Alghamedi, A. Talag or M. Malik). Clinical data and
laboratory parameters from confirmed cases of MERS-
CoV were transcribed onto specially developed case rec-
ord forms. These included the initial manifestations of
respiratory infection, the clinical picture on admission to
the ICU, laboratory indices of organ failure, radiographic
findings, interventions during the ICU stay, treatment
modalities, and final outcome. The Acute Physiology
and Chronic Health Evaluation II (APACHE II) score
was calculated from the data obtained within 24 hours
of admission to the ICU [19]. The Sequential Organ Failure
Assessment (SOFA), score, calculated daily by the phys-
ician in charge of the patient, was also noted [20].
Laboratory investigations
Since the first reported cases of MERS-CoV in Saudi
Arabia in September 2012, all suspected cases in our in-
stitution are strictly isolated and nasopharyngeal swabs
are obtained for initial screening. Deep respiratory sam-
ples (tracheal aspirates or bronchoalveolar lavage fluid)
are obtained from all patients admitted to the ICU with
suspected respiratory infections, in addition to blood
samples to perform cultures and polymerase chain reaction
for common respiratory viruses and atypical microorgan-
isms. Urinary samples were obtained to detect Legionella
antigens in only two patients (Legionella infections are not
common in Saudi patients). Cultures of tracheal aspirates
are analyzed quantitatively and bacterial counts of at least
105 colony-forming units are considered positive. These
investigations are repeated in the ICU whenever secondary
infections are suspected. Clinical specimens aimed at de-
tecting possible MERS-CoV infection are processed and
analyzed at the National Reference Laboratory of the Saudi
Ministry of Health. MERS-CoV infections are identified
using real-time, reverse transcription polymerase chain re-
action (RT-PCR). The standard assays target amplifications
of the upstream E protein (upE gene) and open reading
frame (ORF)1a; both need to be positive to confirm infec-
tion, otherwise another sample is required to confirm the
diagnosis [21]. The sample requires 2 days of processing
for the final results to be available.
Routine laboratory testing in our ICU includes complete
blood counts, coagulation profile, electrolytes, renal
function, liver profile and arterial blood gases. These
parameters are measured on admission to the ICU and at
least once daily thereafter (at 6:00 am) throughout the
ICU stay.
Management and therapy
All patients with suspected or confirmed MERS-CoV
infection were isolated in single rooms, either on the
hospital floor or in the ICU. Patients were admitted
to the ICU according to the guidelines of the Society
of Critical Care Medicine for ICU admission, discharge,
and triage [22]. Patients were classified into four categor-
ies according to their ICU admission priority: priority one
comprised critically ill patients who were unstable and
need intensive treatment and monitoring, with significant
likelihood of recovery; priority two were stable patients
who required intensive monitoring because of the possi-
bility of decompensation; priority three were unstable pa-
tients who had a low likelihood of recovery because of the
severity of acute disease or because of comorbidities; pri-
ority four were those who had little or no anticipated
benefit from ICU admission. Patients classified as priority
one and two and most of those classified as priority three
were admitted to our ICU or full critical care services
were mobilized and provided for in the isolation ward
until a bed was available in the ICU. Priority four patients
were not admitted to the ICU and remained in the isola-
tion ward. General ward patients with MERS-CoV infec-
tion were transferred to the ICU if their condition
deteriorated or organ failure developed. The infection
control precautions recommended by the Saudi Ministry
of Health guidelines were strictly implemented to prevent
possible transmission of MERS-CoV to other patients or
to the healthcare staff [23]. Supportive treatment was pro-
vided according to our standard operating procedures and
in accordance with the surviving sepsis campaign guide-
lines [24, 25]. Antiviral therapies, such as oseltamivir, and
ribavirin/interferon alfa-2a, were prescribed at the discre-
tion of the attending physician. Protective lung ventilation
was applied in mechanically ventilated patients. Prone
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positioning was considered in some patients with severe
refractory hypoxemia. Extracorporeal membrane oxygen-
ation (ECMO) and high-frequency oscillation were also
available as a last resort, when considered necessary by
the attending physician.
Statistical analysis
Statistical analyses were performed using SPSS Statistics 19
for Windows (IBM Corp., Armonk, NY, USA). The
Kolmogorov-Smirnov test was used to verify whether there
were significant deviations from the normality assumption
of continuous variables. Nonparametric tests of compari-
son were used for variables evaluated as not normally dis-
tributed. Difference testing between groups was performed
using Student’s t test, Mann-Whitney test, Chi-square test
and Fisher’s exact test, as appropriate. Friedman’s test was
used to assess the time course of organ function.
To identify the risk factors for death in the ICU, we
performed multivariable logistic regression analyses. Due
to the relatively small number of deaths in our study, we
adjusted only for the severity of illness on admission to
the ICU (APACHE II score) and the degree of organ
dysfunction as assessed by admission SOFA score.
Potential risk factors for ICU mortality were selected
among the demographic characteristics, comorbidities,
mode of acquisition of MERS-CoV, initial manifestations,
procedures and therapies, and superimposing infections.
Variables yielding P <0.2 in the univariate analysis, APA-
CHE II score and SOFA score were included in a multi-
variable logistic regression analysis. These variables were
introduced separately into multivariable models including
APACHE II and SOFA scores on admission to the ICU.
Adjusted odds ratios (OR) and 95 % confidence of interval
(CI) were computed. None of the covariates simultan-
eously introduced in a multivariable model were collinear.
Data are presented as mean ± standard deviation (SD),
median value (25th–75th interquartile range [IQR]) or
number (%), as appropriate. All statistics were two-tailed
and a P < 0.05 was considered statistically significant.
Results
Characteristics of the study cohort
During the observation period, 70 cases with confirmed
MERS-CoV infections were diagnosed in our institution
[11] (Fig. 1); 21 patients were managed in the hospital
ward, 18 patients were admitted to other ICUs or received
critical care service in the ward, and 31 patients were
admitted to our ICU (12 between October 1, 2012 and
December 31, 2013 and 19 between January 1 and May
31, 2014). Patients were admitted to our ICU because of
respiratory failure (PaO2/FiO2 < 250 mmHg).
The mean age of the patients admitted to our ICU
(n = 31) was 59 (SD 20) years and 22 (71 %) were males.
The characteristics of these patients on admission to the
ICU are shown in Table 1. Eighteen (58.1 %) patients had
community-acquired MERS-CoV infection, while for 13
(47.9 %), including two healthcare staff, infection was
acquired in the hospital. Twenty-seven patients (87.1 %)
had at least one comorbidity. The median number of con-
comitant comorbid conditions was three (IQR: 2–4).
Clinical manifestations
Initial clinical manifestations had occurred at a median
of 2 days (IQR: 2–4) prior to hospital admission. Patients
had been treated for a median of 5 days (IQR: 2–9) in
general hospital wards before their admission to the
ICU. Only four patients (12.9 %) were admitted to the
ICU on arrival at the hospital. Cough and tachypnea
were reported in all patients. Other common initial
symptoms were fever (87.1 %), abdominal pain (29 %),
sore throat (25.8 %), and fatigue (25.8 %) (Additional file 1).
Crackles (93.5 %), tachycardia (67.7 %), and rhonchi
(32.3 %) were the most commonly identified initial physical
signs. Bilateral pulmonary infiltrates were present in the
chest X-rays of 24 (77.4 %) patients and lobar infiltrates in
six (19.4 %). Only one patient had a normal chest X-ray at
the time of admission to the ICU.
Microbiology and co-existing infections
On admission to the ICU, no patients had microbio-
logically proven co-existing bacterial pneumonia. Sec-
ondary infections, as evident from positive quantitative
cultures of deep tracheal aspirates, occurred in 18
(58.1) patients within a median of 3 days (IQR: 3–8)
after admission to the ICU. The most commonly isolated
microorganisms were Acinetobacter baumannii (25.8 %),
Fig. 1 Flow chart representing patients’ inclusion and in-hospital
mortality rates according to the admission facility. ICU intensive care
unit, MERS-CoV Middle East respiratory syndrome coronavirus
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Pseudomonas aeruginosa (12.9 %) and Candida species
(9.7 %) (Additional file 2). Sputum cultures were positive
in only four patients. Three patients had evidence of nasal
colonization with methicillin-resistant Staphylococcus
aureus (MRSA) without further microbiologic evidence
of bacterial pneumonia.
Only four (12.9 %) patients had positive blood cultures;
Acinetobacter baumannii (n = 2), Escherichia coli (n = 1),
methicillin-resistant Staphylococcus aureus (n = 1), and
vancomycin-resistant Enterococcus species (n = 1).
Procedures and therapy
Invasive mechanical ventilation was applied in 27
(87.1 %) patients during the ICU stay; 18 (58.1 %) within
24 hours of admission to the ICU, and 14 (45.5 %) pa-
tients received noninvasive ventilation (Table 2). Eleven
(35.5 %) patients were treated with high-frequency oscil-
lation and five (16.1 %) with prone positioning. Only one
patient received ECMO. The ventilatory parameters are
presented in Additional file 3. Vasopressor therapy using
norepinephrine was initiated in 25 (80.6 %) patients
Table 1 Characteristics of patients on admission to the intensive care unit
All patients Nonsurvivors Survivors P value
N 31 23 8
Age in years (mean ± SD) 59 ± 20 63 ± 19 46 ± 20 0.048
Male, n (%) 22 (71.0) 15 (65.2) 7 (87.3) 0.379
Body mass index in kg/m2 (mean ± SD) 29.8 ± 7.6 29.3 ± 7.1 31.2 ± 9.2 0.707
Severity scores (mean ± SD)
APACHE II score 24.2 ± 9.5 26.4 ± 8.5 17.8 ± 9.7 0.034
SOFA score 10.7 ± 3.5 11.7 ± 3.1 8.0 ± 3.2 0.01
Acquisition of pneumonia, n (%) 0.689
Community-acquired 18 (58.1) 14 (60.9) 4 (50.0)
Hospital-acquired 13 (41.9) 9 (39.1) 4 (50.0)
Comorbidities, n (%)
Diabetes mellitus 17 (54.8) 13 (56.5) 4 (50.0) 1.00
Arterial hypertension 16 (51.6) 14 (60.9) 2 (25.0) 0.113
Immunosuppressive drugs 7 (22.6) 5 (21.7) 2 (25.0) 1.00
Chronic heart failure 6 (19.4) 4 (17.4) 2 (25.0) 1.00
Chronic kidney disease 6 (19.4) 4 (17.4) 2 (25.0) 0.634
Cerebrovascular accidents 5 (16.1) 4 (17.4) 1 (12.5) 1.00
Coronary artery disease 4 (12.9) 3 (13.0) 0 (0.0) 1.00
Steroid use 3 (9.6) 3 (13.0) 0 (0.0) 0.161
COPD 3 (9.7) 2 (8.7) 1 (12.5) 1.00
Smoking 3 (9.7) 1 (4.3) 2 (25.0) 0.156
Chronic liver disease 3 (9.7) 3 (13.0) 0 (0.0) 0.550
Hypothyroid 3 (9.7) 3 (13.0) 0 (0.0) 0.550
Cancer 2 (6.5) 2 (8.7) 0 (0.0) 1.00
Epilepsy 2 (6.5) 1 (4.3) 1 (12.5) 0.456
Dyslipidemia 1 (3.2) 1 (4.3) 0 (0.0) 1.00
Asthma 1 (3.2) 1 (4.3) 0 (0.0) 1.00
Bronchiectasis 1 (3.2) 1 (4.3) 0 (0.0) 1.00
Obstructive sleep apnea 1 (3.2) 1 (4.3) 0 (0.0) 1.00
Number of comorbidities, median (IQR) 3 (2–4) 3 (2–4) 3 (1–4) 0.580
ICU mortality, n (%) 23 (74.2) 23 (100) - NA
ICU length of stay in days [median, (IQR)] 9 (4–16) 10 (4–16) 9 (4–17) 0.912
Hospital length of stay in days [median, (IQR)] 12 (4–16) 10 (4–16) 18 (14–72) 0.002
APACHE acute physiology and chronic health evaluation, COPD chronic obstructive pulmonary disease, ICU intensive care unit, IQR interquartile range, NA not
applicable, SD standard deviation, SOFA sequential organ failure assessment
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during the ICU stay, nine (29 %) within 24 hours of ICU
admission, and 16 (51.6 %) patients received continuous
renal replacement therapy (Table 2). Oseltamivir was ad-
ministered to 20 (64.5 %) patients for a median of 5 days
(IQR: 3–5). Combined ribavirin plus interferon alfa-2a
therapy was used in 13 (41.9 %) patients (Table 2). All
patients received at least one antimicrobial agent during
the ICU stay (Additional file 2). Antifungal therapy
was only used in four of the five patients with positive
cultures for Candida but the necessity of this therapy is
uncertain.
Morbidity and mortality
The overall ICU mortality rate was 74.2 % (n = 23). The
median ICU and hospital lengths of stay were 9 (IQR:
4–16) and 12 (IQR: 4–16) days, respectively. The major
causes of death were hypoxemic respiratory failure
(52.2 %) and refractory septic shock (26.1 %). One
patient died from sudden cardiac arrest after ICU
discharge but while still in the hospital. Furthermore, one
patient died within 1 year after discharge from the ICU
because of septic shock related to an infected wound. Only
one patient was lost to follow-up after hospital discharge.
The SOFA score and Glasgow Coma Scale (GCS)
increased markedly over the first 2 weeks in the ICU
in the whole cohort, while other parameters of organ
function remained largely unchanged (Additional file 3).
Compared with those who were discharged alive from the
ICU, nonsurvivors were older, had higher APACHE II and
SOFA scores on admission to the ICU, and were more
likely to require invasive mechanical ventilation and vaso-
pressor therapy and to have been ventilated using high-
frequency oscillation (Tables 1 and 2, and Additional files
1 and 2). Nonsurvivors had a persistently low PaO2/FiO2
throughout the first 2 weeks in the ICU, whereas survivors
showed a slight increase over time (Fig. 2). After adjust-
ment for the severity of illness and the degree of organ
dysfunction, the need for vasopressors was the only inde-
pendent risk factor for death in the ICU (OR 18.33, 95 %
confidence interval 1.11–302.1, P 0.04) (Additional file 4).
Discussion
The 31 critically ill patients with confirmed MERS-CoV
infection in our cohort frequently had organ failure with
an overall mortality rate greater than 74 %. Comorbidities
were common in this cohort of patients. Not surprisingly,
mortality in the ICU was associated with older age, severe
disease and organ failure. The need for vasopressor ther-
apy was an independent risk factor of death in the ICU.
Since the first reported case of MERS-CoV infection in
2012, several authors have described various cohorts of
patients with this serious infection [8, 10–12, 14, 15, 26].
Table 2 Procedures and therapies
All patients Nonsurvivors Survivors P valuea
N 31 23 8
Noninvasive ventilation, n (%);
days, median (IQR)
14 (45.2);
2 (1–3)
8 (34.8);
2 (1–3)
6 (75.0);
2 (1–4)
0.097
Invasive ventilation, n (%);
days, median (IQR)
27 (87.1);
8 (4–17)
22 (95.7);
8 (2–17)
5 (62.5);
11 (5–17)
0.043
High-frequency oscillation 11 (35.5) 11 (47.8) 0 (0.0) 0.028
Prone positioning, n (%);
days, median (IQR)
5 (16.1);
4 (2–5)
5 (21.7);
4 (2–5)
0 (0.0);
0 (0.0)
1.00
ECMO, n (%);
days, median (IQR)
1 (3.2);
13 (13–13)
1 (4.3);
13 (13–13)
0 (0.0);
0 (0.0)
1.00
Vasopressorsb, n (%);
days, median (IQR)
25 (80.6);
4 (2–9)
22 (95.7);
5 (2–9)
3 (37.5);
3 (2–3)
0.002
Intermittent hemodialysis, n (%);
days, median (IQR)
3 (9.7);
5 (2–5)
2 (8.7);
4 (2–4)
1 (12.5);
7 (7–7)
1.00
Continuous RRT, n (%);
days, median (IQR)
16 (51.6);
6 (2–11)
14 (60.9);
7 (3–11)
2 (25.0);
2 (1–2)
0.113
Medications, n (%)
Oseltamivir 20 (64.5) 15 (65.2) 5 (62.5) 0.484
Ribavirin/interferon alfa-2a 13 (41.9) 9 (39.1) 4 (50.0) 0.507
Neuromuscular blockers 12 (38.7) 10 (43.5) 2 (25.0) 0.465
Steroidsc 8 (25.8) 6 (26.1) 2 (25.0) 0.954
ECMO extracorporeal membrane oxygenator, IQR interquartile range, RRT renal replacement therapy
aComparisons done for frequencies
bNorepinephrine
cIntravenous hydrocortisone (200–300 mg per day) in four patients and methyprednisolone in four patients (maintenance therapy for underlying disease)
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Most of the reports included all microbiologically
confirmed cases, irrespective of the severity of illness
and the clinical course. Indeed, the clinical features of
MERS-CoV infection range from asymptomatic or
mild disease to acute respiratory distress syndrome
(ARDS) and multi-organ failure [13, 27]. The most
severe cases, which require admission to the ICU, are
potentially life-threatening and represent a major chal-
lenge to the healthcare system. To date, only three studies
have reported the clinical characteristics and outcomes of
patients with MERS-CoV infection who were admitted to
the ICU; collectively including a total of only 34 patients
[16–18]. Arabi et al. included 12 patients admitted to two
ICUs in Riyadh and one in Al-Hasa in the central and
eastern parts of the country, respectively [17]. The
other two reports were both from Jeddah, western
Saudi Arabia. Al-Hameed et al. included eight patients,
whereas Khalid et al. described the clinical course and
outcomes of 14 patients with severe MERS-CoV infec-
tion and ARDS [16, 18]. Our facility is a large tertiary-
care medical center in Riyadh, central Saudi Arabia.
We herein provide a detailed account of the largest
single cohort of critically ill MERS-CoV infected patients
reported thus far.
In agreement with previous reports from Saudi Arabia,
comorbid conditions were common in our patients with
MERS-CoV infections with a median of three comorbid-
ities per patient [10, 11, 15, 17]. In contrast, only 54.8 %
of the 186 individuals involved in the recent MERS-CoV
outbreak in South Korea had any preexisting chronic
medical conditions [8]. However, only 29.6 % of patients in
the Korean outbreak were aged 65 years or older and
nearly half (46.2 %) were caregivers or healthcare personnel
[8]. The differences in the demographic characteristics of
our cohorts and the mode of acquisition of MERS-CoV in-
fection may explain, at least in part, the discrepancy in the
patterns of associated comorbidities between the Saudi and
Korean cohorts.
The respiratory manifestations of MERS-CoV infection
in our cohort were similar to those observed in previous
reports from Saudi patients [10, 11, 14, 15, 17]. Cough
and tachypnea occurred in all patients and 77 % of cases
had bilateral pulmonary infiltrates, denoting severe re-
spiratory illness, which required a median of 5 days to
reach the peak of clinical deterioration such that ICU
admission and organ support therapy were required.
Gastrointestinal manifestations, such as abdominal pain,
diarrhea, vomiting, and abdominal tenderness, were rela-
tively common in our cohort. This was also a common
finding in the previous literature in patients with MERS-
CoV infection as well as those with severe acute respira-
tory syndrome (SARS) [10, 11, 15, 17, 28, 29].
Our data confirm previous studies that reported a high
prevalence of nonrespiratory organ failure in critically ill
patients with MERS-CoV [16, 17]. The mechanisms of
organ dysfunction and failure in these patients are yet to
be determined. Cytokine dysregulation has been sug-
gested to be involved in the pathophysiology of MERS-
CoV-related organ failure. Direct viral invasion may also
occur as the virus was recovered from urine and stool in
one patient [30]. In agreement with the results of the
previous reports on critically ill patients with MERS-CoV
infection [16–18], more than 80 % of our patients received
vasopressor support, underscoring the high prevalence of
cardiovascular dysfunction in these patients, and suggest-
ing that disturbances in tissue perfusion may also have
been involved in the pathophysiology of the organ failure.
Lower rates of vasopressor support have been reported in
patients with SARS [10, 11, 15, 17, 28, 29] with, as a result,
lower mortality rates than those reported in patients with
MERS-CoV infections.
Even though overall mortality rate was high in our co-
hort, it is still comparable with rates reported in previ-
ous studies (58.3–64.3 %) [16–18]. In all studies, almost
all patients had significant comorbidities and median
APACHE II scores of 25 or higher. We observed sig-
nificantly higher APACHE II and SOFA scores in ICU
nonsurvivors compared to those who survived severe
MERS-CoV infection, underscoring the strong associ-
ation between mortality and the severity of disease.
Epidemiological analyses have suggested that MERS-
CoV is unlikely to trigger sustained human epidemics at
present [31, 32]. Nevertheless, nosocomial outbreaks have
resulted in considerable morbidity and mortality, in
addition to disruption of medical services and substantial
economic losses [9, 33, 34]. The most severe infections
usually require ICU admission, necessitate major resource
utilization and result in high fatality rates. Identifying
possible risk factors for poor prognosis in patients with
MERS-CoV infection is therefore crucial to enable
Fig. 2 Box plot representing the time course of PaO2/FiO2
according to ICU outcome. *P < 0.005 compared to survivors
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appropriate allocation of healthcare resources and early
transfer of high-risk patients to the appropriate medical
facilities. Our data show that the need for vasopressor
therapy was an independent risk factor for death in the
ICU. Indeed, the major causes of death in our study were
hypoxemic respiratory failure and refractory septic shock,
which confirm the role of respiratory and cardiovascular
system failures as determinants of outcome in this po-
pulation. This was also evident from the persistent
hypoxemia observed in the nonsurvivors. To date,
published data on the risk factors for poor prognosis spe-
cific to critically ill patients with MERS-CoV infection are
lacking. In cohort studies of patients with any degree of
severity of MERS-CoV infection, older age, diabetes,
chronic renal failure, chronic respiratory disease, high viral
load in lower respiratory tract samples, shorter incubation
period and MERS-CoV viremia have all identified as inde-
pendent predictors of mortality [11, 14, 35–37].
Secondary respiratory infections occurred commonly in
this cohort, predominantly with Gram-negative bacteria.
Although Candida species were frequently isolated, these
are probably not relevant as respiratory pathogens and the
necessity of antifungal therapy is uncertain. Interestingly,
Acinetobacter baumannii, which is an emerging fatal in-
fection in ICU patients worldwide, was isolated from deep
tracheal aspirates in one in four patients. This may ex-
plain, at least in part, the relatively high mortality rates in
this cohort.
Specific therapeutic options for MER-CoV infections are
limited and their efficacy is not well established [38].
All patients in this report received antiviral treatment
with either oseltamivir or combined ribavirin/interferon
alfa-2a therapy; two patients received both. Although
a previous study from the same institution showed
that combined ribavirin/interferon alfa-2a therapy was
associated with significant improvement in survival at
14 days, this benefit was not maintained at 28 days
after the onset of the disease [39]. The retrospective
and observational nature of this study does not allow
precise assessment of the efficacy of these therapies.
In the absence of a vaccine or a specific treatment,
prevention of viral transmission through adequate infec-
tion control methods is the mainstay in the management
of MERS-CoV outbreaks. Appropriate isolation of patients
with suspected or proven infections is crucial. In view of
the high fatality rates of these patients in the ICU, it may
be reasonable to closely monitor patients with suspected
infections in the general wards for early signs of organ
dysfunction to prevent unnecessary delay in the provision
of intensive care services and reduce mortality rates in
these patients.
Our study has some limitations. We included patients
with confirmed MERS-CoV infection from one ICU
of a large medical center. Possible variations in the
geographic distribution of the disease and in local prac-
tice may hinder extrapolation of these data to other co-
horts in Saudi Arabia and other countries. The relatively
low number of patients may have biased the statistical
comparisons presented in this report and overestimated
mortality rates. Multivariable adjustment was also limited
to the variables included in the models. Collaborative ef-
forts are needed to provide an insight into the risk factors
for poor prognosis in these patients.
Conclusions
MERS-CoV infections requiring admission to the ICU
are associated with high morbidity and mortality rates.
The need for vasopressor therapy is the main risk factor
for death in these patients.
Key messages
 This report describes the clinical features and
outcomes of 31critically ill patients with confirmed
Middle East respiratory syndrome coronavirus
(MERS-CoV) infection.
 Patients with MERS-CoV infections frequently had
organ failure, and mortality rates were greater than
72 %.
 The need for vasopressor therapy was an
independent risk factor for death in the ICU.
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